BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 35696608)

  • 1. YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation.
    Huang CS; Zhu YQ; Xu QC; Chen S; Huang Y; Zhao G; Ni X; Liu B; Zhao W; Yin XY
    Clin Transl Med; 2022 Jun; 12(6):e848. PubMed ID: 35696608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YBX1 promotes stemness and cisplatin insensitivity in intrahepatic cholangiocarcinoma via the AKT/β-catenin axis.
    Shi X; Hu Z; Bai S; Zong C; Xue H; Li Y; Li F; Chen L; Xuan J; Xia Y; Wei L; Shen F; Wang K
    J Gene Med; 2024 May; 26(5):e3689. PubMed ID: 38676365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of MGMT promotes proliferation of intrahepatic cholangiocarcinoma by regulating p21.
    Chen J; Li Z; Chen J; Du Y; Song W; Xuan Z; Zhao L; Song G; Song P; Zheng S
    Clin Transl Oncol; 2020 Mar; 22(3):392-400. PubMed ID: 31264147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. METTL3 promotes intrahepatic cholangiocarcinoma progression by regulating IFIT2 expression in an m
    Xu QC; Tien YC; Shi YH; Chen S; Zhu YQ; Huang XT; Huang CS; Zhao W; Yin XY
    Oncogene; 2022 Mar; 41(11):1622-1633. PubMed ID: 35094011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VIRMA facilitates intrahepatic cholangiocarcinoma progression through epigenetic augmentation of TMED2 and PARD3B mRNA stabilization.
    Xu H; Lin X; Li Z; He X; Li Y; Qiu L; Lu L; Liu B; Zhan M; He K
    J Gastroenterol; 2023 Sep; 58(9):925-944. PubMed ID: 37391589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High expression of protein tyrosine kinase 7 significantly associates with invasiveness and poor prognosis in intrahepatic cholangiocarcinoma.
    Jin J; Ryu HS; Lee KB; Jang JJ
    PLoS One; 2014; 9(2):e90247. PubMed ID: 24587299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autocrine parathyroid hormone-like hormone promotes intrahepatic cholangiocarcinoma cell proliferation via increased ERK/JNK-ATF2-cyclinD1 signaling.
    Tang J; Liao Y; He S; Shi J; Peng L; Xu X; Xie F; Diao N; Huang J; Xie Q; Lin C; Luo X; Liao K; Ma J; Li J; Zhou D; Li Z; Xu J; Zhong C; Wang G; Bai L
    J Transl Med; 2017 Nov; 15(1):238. PubMed ID: 29178939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. H2A.Z regulates tumorigenesis, metastasis and sensitivity to cisplatin in intrahepatic cholangiocarcinoma.
    Yang B; Tong R; Liu H; Wu J; Chen D; Xue Z; Ding C; Zhou L; Xie H; Wu J; Zheng S
    Int J Oncol; 2018 Apr; 52(4):1235-1245. PubMed ID: 29532867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N6-methyladenosine-modified circSLCO1B3 promotes intrahepatic cholangiocarcinoma progression via regulating HOXC8 and PD-L1.
    Li J; Xu X; Xu K; Zhou X; Wu K; Yao Y; Liu Z; Chen C; Wang L; Sun Z; Jiao D; Han X
    J Exp Clin Cancer Res; 2024 Apr; 43(1):119. PubMed ID: 38641828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of glucose and glutamine metabolism to overcome cisplatin resistance in intrahepatic cholangiocarcinoma.
    Yang SM; Kim J; Lee JY; Lee JS; Lee JM
    BMB Rep; 2023 Nov; 56(11):600-605. PubMed ID: 37401237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YTHDF1 promotes intrahepatic cholangiocarcinoma progression via regulating EGFR mRNA translation.
    Huang X; Zhu L; Wang L; Huang W; Tan L; Liu H; Huo J; Su T; Zhang M; Kuang M; Li X; Dai Z; Xu L
    J Gastroenterol Hepatol; 2022 Jun; 37(6):1156-1168. PubMed ID: 35233828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N6-methyladenosine reader YTHDF2 promotes multiple myeloma cell proliferation through EGR1/p21
    Liu R; Miao J; Jia Y; Kong G; Hong F; Li F; Zhai M; Zhang R; Liu J; Xu X; Wang T; Liu H; Hu J; Yang Y; He A
    Oncogene; 2023 May; 42(20):1607-1619. PubMed ID: 37012388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin Disrupts Proteasome Bounce-Back Effect through Suppressing ZEB1/Nfe2l1 in Cholangiocarcinoma.
    Xiang Y; Jia M; Gao Y; Yang F; Wang T; Dai R; Wang M; Miao H
    Front Biosci (Landmark Ed); 2024 Mar; 29(3):106. PubMed ID: 38538281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Trojan Horse Nanotherapy Strategy Targeting the cPKM-STMN1/TGFB1 Axis for Effective Treatment of Intrahepatic Cholangiocarcinoma.
    Chen ZW; Kang FP; Xie CK; Liao CY; Li G; Wu YD; Lin HY; Zhu SC; Hu JF; Lin CF; Huang Y; Tian YF; Huang L; Wang ZW; Chen S
    Adv Sci (Weinh); 2023 Nov; 10(32):e2303814. PubMed ID: 37789644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma.
    Hao XY; Cai JP; Liu X; Chen W; Hou X; Chen D; Lai JM; Liang LJ; Yin XY
    Chin J Cancer; 2016 Jul; 35(1):70. PubMed ID: 27469137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
    Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
    Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of ROS-FIG inhibits cell proliferation, colony‑formation, cell cycle progression, migration and invasion, while inducing apoptosis in intrahepatic cholangiocarcinoma cells.
    Deng G; Hu C; Zhu L; Huang F; Huang W; Xu H; Nie W
    Int J Mol Med; 2014 Sep; 34(3):661-8. PubMed ID: 24968753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bufalin targeting CAMKK2 inhibits the occurrence and development of intrahepatic cholangiocarcinoma through Wnt/β-catenin signal pathway.
    Zhang H; Dong X; Ding X; Liu G; Yang F; Song Q; Sun H; Chen G; Li S; Li Y; Wang M; Guo T; Zhang Z; Li B; Yang L
    J Transl Med; 2023 Dec; 21(1):900. PubMed ID: 38082327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening a redox library identifies the anti-tumor drug Hinokitiol for treating intrahepatic cholangiocarcinoma.
    Bai P; Ge C; Yang H; Chen H; Wan L; Zhang Y; Zhang B; Zeng Q; Fan Z; Pei X; Yue W; Yan X
    Front Biosci (Landmark Ed); 2022 Jan; 27(1):18. PubMed ID: 35090323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-related RNA signature predicts outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma.
    Zeng TM; Pan YF; Yuan ZG; Chen DS; Song YJ; Gao Y
    Front Immunol; 2022; 13():943066. PubMed ID: 36159865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.